A detailed history of Brilliance Asset Management LTD transactions in Zai Lab LTD stock. As of the latest transaction made, Brilliance Asset Management LTD holds 436,527 shares of ZLAB stock, worth $10.9 Million. This represents 2.13% of its overall portfolio holdings.

Number of Shares
436,527
Previous 435,926 0.14%
Holding current value
$10.9 Million
Previous $6.98 Million 8.33%
% of portfolio
2.13%
Previous 1.61%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$13.72 - $21.55 $8,245 - $12,951
601 Added 0.14%
436,527 $7.57 Million
Q4 2023

Feb 13, 2024

BUY
$22.97 - $30.58 $6.4 Million - $8.53 Million
278,841 Added 177.51%
435,926 $11.9 Million
Q3 2023

Nov 13, 2023

BUY
$22.72 - $31.49 $3.57 Million - $4.95 Million
157,085 New
157,085 $3.82 Million
Q3 2022

Nov 09, 2022

SELL
$34.2 - $51.69 $44.6 Million - $67.4 Million
-1,303,289 Reduced 98.43%
20,775 $711,000
Q2 2022

Aug 12, 2022

SELL
$23.14 - $49.68 $7.12 Million - $15.3 Million
-307,823 Reduced 18.86%
1,324,064 $45.9 Million
Q1 2022

Apr 29, 2022

SELL
$27.77 - $64.4 $46.9 Million - $109 Million
-1,689,083 Reduced 50.86%
1,631,887 $71.8 Million
Q4 2021

Feb 11, 2022

BUY
$54.9 - $105.21 $12.6 Million - $24.1 Million
228,750 Added 7.4%
3,320,970 $209 Million
Q3 2021

Nov 12, 2021

SELL
$105.0 - $178.37 $5.15 Million - $8.75 Million
-49,062 Reduced 1.56%
3,092,220 $326 Million
Q2 2021

Aug 13, 2021

BUY
$125.11 - $180.0 $27.2 Million - $39.1 Million
217,393 Added 7.44%
3,141,282 $556 Million
Q1 2021

May 14, 2021

SELL
$126.27 - $191.71 $15.5 Million - $23.6 Million
-123,087 Reduced 4.04%
2,923,889 $390 Million
Q4 2020

Feb 16, 2021

BUY
$81.94 - $135.34 $194 Million - $320 Million
2,362,244 Added 344.99%
3,046,976 $412 Million
Q3 2020

Nov 13, 2020

BUY
$73.3 - $89.48 $50.2 Million - $61.3 Million
684,732 New
684,732 $56.9 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.43B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Brilliance Asset Management LTD Portfolio

Follow Brilliance Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brilliance Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Brilliance Asset Management LTD with notifications on news.